BMS-986525

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Phase 1

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

RecruitingNCT07325136

Bristol-Myers SquibbRelapsed/Refractory Small Cell Lung Cancer

Start: 2026-02-03End: 2029-04-24Target: 240Updated: 2026-09-14

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

Not yet recruitingCTIS2025-524090-16-00

Bristol-Myers Squibb Services Unlimited CompanyRelapsed/Refractory Small Cell Lung Cancer

Target: 5Updated: 2026-05-18